SCHEMBL5401732

SCHEMBL5401732

OC1CCCN(Cc2ccccc2)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.76
NPC1 O15118 1/20 0.64
RAB9A P51151 1/20 0.64
ACHE P22303 3/20 0.59
CCR3 P51677 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
SIGMAR1 Q99720 2/20 0.57
MEN1 O00255 1/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.55
DRD2 P14416 1/20 0.54
DRD4 P21917 1/20 0.54
DRD3 P35462 1/20 0.54
CXCR4 P61073 1/20 0.54
BCHE P06276 1/20 0.53
BACE1 P56817 1/20 0.53
HRH3 Q9Y5N1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22432783 1.00 ALDH1A1 (0.76) ALDH1A1NPC1RAB9AACHECCR3
SCHEMBL24200041 0.96 ALDH1A1 (0.81) ALDH1A1NPC1RAB9AACHECCR3
SCHEMBL24200039 0.93 ALDH1A1 (0.76) ALDH1A1NPC1RAB9AACHECCR3
SCHEMBL266138 0.93 NPC1 (0.71) ALDH1A1NPC1RAB9AACHECCR3
SCHEMBL11398679 0.92 ALDH1A1 (0.66) ALDH1A1NPC1RAB9AACHECCR3
Hydrochloric Acid SCHEMBL28652893 0.91 NPC1 (0.69) ALDH1A1NPC1RAB9AACHECCR3
Methane SCHEMBL28444324 0.91 NPC1 (0.69) ALDH1A1NPC1RAB9AACHECCR3
Ethane SCHEMBL27302230 0.89 ACHE (0.68) ALDH1A1NPC1RAB9AACHECCR3
SCHEMBL1787570 0.86 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL1552926 0.86 ALDH1A1 (1.00) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-04-28 US disclosed
EP-3939954-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE Otsuka Pharmaceutical Co., Ltd. (JP) 2022-01-19 EP disclosed
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE MGMT, FANCD2, ADAR ALDH1A1 2354/4885NPC1 4169/4885RAB9A 2457/4885
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA ALDH1A1 3541/4885NPC1 837/4885RAB9A 85/4885
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 ALDH1A1 2454/4885NPC1 116/4885RAB9A 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.